Now, more than ever, the assurance that therapeutic and preventative drugs have gone through rigorous and regulated quality control is a primary driver of patient trust in personalised medicines and vaccines. The nature of the pharmaceutical industry is transforming to focus more on biologic drug products and parenteral treatments manufactured in cGMP environments vastly different from traditional oral tablets or capsules. Despite these industry changes, the identification of APIs, excipients and cell culture medias for drug manufacturing and the identification of drug substances remains a constant need, not to mention the importance of brand protection against counterfeits.
Explore the evolving role of handheld and portable instruments to drive quality improvements and manufacturing success in 2021
Webinar Details
Now, more than ever, the assurance that therapeutic and preventative drugs have gone through rigorous and regulated quality control is a primary driver of patient trust in personalised medicines and vaccines. The nature of the pharmaceutical industry is transforming to focus more on biologic drug products and parenteral treatments manufactured in cGMP environments vastly different from traditional oral tablets or capsules. Despite these industry changes, the identification of APIs, excipients and cell culture medias for drug manufacturing and the identification of drug substances remains a constant need, not to mention the importance of brand protection against counterfeits.
The information below is required for social login
Sign In
Create New Account
Explore the evolving role of handheld and portable instruments to drive quality improvements and manufacturing success in 2021
Webinar Details
Now, more than ever, the assurance that therapeutic and preventative drugs have gone through rigorous and regulated quality control is a primary driver of patient trust in personalised medicines and vaccines. The nature of the pharmaceutical industry is transforming to focus more on biologic drug products and parenteral treatments manufactured in cGMP environments vastly different from traditional oral tablets or capsules. Despite these industry changes, the identification of APIs, excipients and cell culture medias for drug manufacturing and the identification of drug substances remains a constant need, not to mention the importance of brand protection against counterfeits.
Date: 9th December 2020
Time: 10:00 PM +08
Key learning outcomes:
Speakers
Dean Stuart, Product Manager
Fisher Scientific
Eden Couillard, Scientist III, Thermo
Thermo Fisher Scientific